Method for preparing oxetan-2-yl methylamine or salt thereof
The process in the prior art was solved by using trimethyl sulfonate halide or trimethyl sulfoxide and base in the preparation of oxetane-2-ylmethylamine, combined with further treatment of acid and condensing agent. The problems of low yield and safety risks have achieved efficient and safe preparation of oxetane-2-ylmethylamine.
Patent Information
- Application Number
- CN202410686028.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-15
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, the process yield of preparing oxetane-2-ylmethylamine is low, the use of heavy metals and highly toxic azides has a safety risk, and the ring expansion yield is relatively low, resulting in increased cost of the entire process and safety risks. .
Trimethyl sulfonium halide or trimethyl sulfoxide reacts with alkali under specific conditions to form oxetane-2-ylmethylamine, followed by further reaction in the presence of acid or condensing agent, and finally in the presence of hydrazine hydrate Convert to the target compound.
The production process yield of oxetane-2-ylmethylamine is improved, the use of heavy metals and highly toxic azides is avoided, safety risks are reduced, and process costs are optimized.
Smart Images

Figure CN119059994A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medicine and relates to a method for preparing oxetane-2-ylmethylamine or a salt thereof. Background Art
[0002] The compound oxetane-2-ylmethylamine is commonly used in the preparation of GLP-1 receptor agonists and is a key intermediate in the preparation of methyl 2-(chloromethyl)-1-oxetane-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate.
[0003] WO2018 / 109607 discloses a five-step process for preparing (S)-oxetane-2-ylmethylamine starting from (S)-2-((benzyloxy)methyl)oxirane. The overall process yield is low, and the process uses azide, which is highly toxic and sensitive to heat and shock, prone to explosive decomposition. This poses significant safety risks during scale-up.
[0004] WO2021 / 118906 discloses a four-step process for preparing oxetane-2-ylmethylamine using epichlorohydrin as a raw material. The overall process route is short, but the ring expansion yield is low, and heavy metals such as palladium are used to remove the benzyl protecting group, which invisibly increases the overall process cost. Summary of the Invention
[0005] The present disclosure provides a new method for preparing a compound of formula E or a salt thereof
[0006] The method comprises the steps of reacting a compound of formula A under trimethylsulfonium halide / base or trimethylsulfoxide halide / base conditions to form a compound of formula B,
[0007]
[0008] Wherein, Ar is a 6-membered aryl or a 5-6-membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted by halogen, C 1-6 Alkyl or C 1-6 The moiety may be substituted with an alkoxy group, for example, phenyl or pyridyl.
[0009] In some embodiments, the trimethylsulfonium halide is trimethylsulfonium iodide.
[0010] In some embodiments, the trimethylsulfoxide halide is trimethylsulfoxide iodide.
[0011] In some embodiments, the base is selected from potassium tert-butoxide, sodium tert-butoxide, lithium tert-butoxide, potassium tert-amylate, sodium tert-amylate, lithium tert-amylate, potassium hydride, sodium hydride, n-butyllithium, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, or potassium bis(trimethylsilyl)amide.
[0012] In some embodiments, the base is selected from potassium tert-butoxide.
[0013] In some embodiments, the solvent used in the reaction of the compound of formula A is selected from tert-butyl alcohol, dimethyl sulfoxide, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone or tert-amyl alcohol.
[0014] In some embodiments, the solvent used in the reaction of the compound of formula A is selected from tert-butanol.
[0015] In some embodiments, the molar ratio of the compound of formula A to trimethylsulfoxide halide is 1:1 to 1:2, including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2 or any value between two numbers. In other embodiments, the molar ratio of the compound of formula A to trimethylsulfoxide halide is 1:1 to 1:1.5.
[0016] In some embodiments, the molar ratio of the compound of formula A to trimethylsulfoxide halide is 1:1 to 1:1.5.
[0017] In other embodiments, the molar ratio of the compound of formula A to trimethylsulfonium halide is 1:1 to 1:2, including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2 or any value between two numbers. In other embodiments, the molar ratio of the compound of formula A to trimethylsulfonium halide is 1:1 to 1:1.5.
[0018] In other embodiments, the molar ratio of the compound of formula A to trimethylsulfonium iodide is 1:1 to 1:1.5.
[0019] In other embodiments, the molar ratio of the compound of formula A to the base is 1:1 to 1:2, including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2 or any value between two numbers. In other embodiments, the molar ratio of the compound of formula A to the base is 1:1 to 1:1.5.
[0020] In other embodiments, the molar ratio of the compound of formula A to potassium tert-butoxide is 1:1 to 1:1.5.
[0021] Some embodiments provide a method for preparing a compound of formula E or a salt thereof, comprising the step of reacting a compound of formula A under trimethylsulfoxide iodide / potassium tert-butoxide conditions to form a compound of formula B,
[0022]
[0023] Some embodiments provide a method for preparing a compound of formula E or a salt thereof, comprising the step of reacting a compound of formula A under trimethylsulfonium iodide / potassium tert-butoxide conditions to form a compound of formula B,
[0024]
[0025] In some embodiments, the compound of formula A in the method is a compound of formula A-1 The method comprises the steps of reacting a compound of formula A-1 under trimethylsulfoxide halide / base conditions to form a compound of formula B-1,
[0026]
[0027] In some embodiments, the compound of formula A in the method is a compound of formula A-1 The method comprises the steps of reacting a compound of formula A-1 under trimethylsulfonium halide / base conditions to form a compound of formula B-1,
[0028]
[0029] In other embodiments, the compound of formula E in the method is (S)-oxetane-2-ylmethylamine (compound of formula E-1) or (R)-oxetane-2-ylmethylamine (compound of formula E-2),
[0030]
[0031] Some embodiments provide a method for preparing a compound of formula E comprising the step of reacting a compound of formula A-1a under trimethylsulfonium iodide / potassium tert-butoxide conditions to form a compound of formula B-1a,
[0032]
[0033] Some embodiments provide a method for preparing a compound of formula E comprising the steps of reacting a compound of formula A-1a under trimethylsulfoxide halide / potassium tert-butoxide conditions to form a compound of formula B-1a,
[0034]
[0035] Furthermore, the method for preparing the compound of formula E or its salt disclosed herein further comprises the step of reacting the compound of formula B under acidic conditions to form a compound of formula C.
[0036]
[0037] wherein Ar is as defined above.
[0038] In some embodiments, the acid is selected from at least one of trifluoroacetic acid, trimethylsilane, or triethylsilane.
[0039] In other embodiments, the molar ratio of the compound of formula B to the acid is 1:1 to 1:5, including but not limited to 1:1, 1:1.2, 1:1.4, 1:1.6, 1:1.8, 1:2, 1:2.2, 1:2.4, 1:2.6, 1:2.8, 1:3, 1:3.2, 1:3.4, 1:3.6, 1:3.8, 1:4, 1:4.2, 1:4.4, 1:4.6, 1:4.8, 1:5 or any value between two numbers. In other embodiments, the molar ratio of the compound of formula A to the acid is 1:1 to 1:1.4.
[0040] In other embodiments, the molar ratio of the compound of formula A to trifluoroacetic acid is 1:1 to 1:1.4, including but not limited to 1:1, 1:2, 1:3 or 1:4.
[0041] In other embodiments, the molar ratio of the compound of formula A to triethylsilane is 1:1 to 1:2, including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2 or any value between two numbers.
[0042] In other embodiments, the molar ratio of the compound of formula A to triethylsilane is 1:1 to 1:1.5. In some embodiments, the acid is selected from trifluoroacetic acid / triethylsilane.
[0043] In other embodiments, the molar ratio of triethylsilane to trifluoroacetic acid is 1:1 to 1:3, including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, 1:2.6, 1:2.7, 1:2.8, 1:2.9, 1:3 or any value therebetween. In other embodiments, the molar ratio of triethylsilane to trifluoroacetic acid is 1:1 to 1:2.5.
[0044] In some embodiments, the method for preparing the compound of formula E or a salt thereof further comprises the step of reacting the compound of formula B under trifluoroacetic acid / triethylsilane conditions to form a compound of formula C.
[0045]
[0046] In some embodiments, the compound of formula B in the method is a compound of formula B-1 The method comprises the steps of reacting a compound of formula B-1 under trifluoroacetic acid / triethylsilane conditions to form a compound of formula C,
[0047]
[0048] In some embodiments, the method for preparing a compound of formula E-1 or a salt thereof comprises the step of reacting a compound of formula B-1a under trifluoroacetic acid / triethylsilane conditions to form a compound of formula C-1a.
[0049]
[0050] On the other hand, the method for preparing the compound of formula E or its salt further comprises the step of converting the compound of formula C into the compound of formula D,
[0051] Among them, R 1 、R 2 are each independently selected from hydrogen, halogen or C 1-6 Alkyl, or R 1 and R 2 Together with adjacent carbon atoms, a 6-membered aryl or 5-6 heteroaryl group is formed, wherein the aryl or heteroaryl group is optionally substituted by halogen, C 1-6 Alkyl or C 1-6 Alkoxy substituted.
[0052] In some embodiments, the method of preparing a compound of formula E or a salt thereof comprises the step of reacting a compound of formula C with a compound of formula Z to form a compound of formula D,
[0053]
[0054] In some embodiments, the compound of formula C is reacted with a compound of formula Z in the presence of a condensing agent to form a compound of formula D.
[0055] In other embodiments, the molar ratio of the compound of formula C to the condensing agent is 1:1 to 1:2, including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2 or any value between two numbers.
[0056] In other embodiments, the molar ratio of the compound of formula C to the condensing agent is 1:1.
[0057] The condensing agent disclosed herein is selected from, but not limited to, diisopropyl azodicarboxylate (DIAD) or diethyl azodicarbonate (DEAD).
[0058] In other embodiments, the compound of formula C is reacted with a compound of formula Z in the presence of a condensing agent / triphenylphosphine to form a compound of formula D.
[0059] In other embodiments, the molar ratio of the compound of formula C to triphenylphosphine is 1:1 to 1:2, including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2 or any value between two numbers.
[0060] In other embodiments, the molar ratio of the compound of formula C to triphenylphosphine is 1:1.1.
[0061] In other embodiments, the compound of formula C is reacted with a compound of formula Z in the presence of diisopropyl azodicarboxylate / triphenylphosphine to form a compound of formula D.
[0062] In other embodiments, the solvent used in the reaction of the compound of formula C is selected from aprotic polar solvents, such as tetrahydrofuran.
[0063] In other embodiments, the reaction type of the compound of formula C and the compound of formula Z is a Mitsunobu reaction. The specific reaction conditions can be referred to "Organic Reactions, Reagents and Rules" edited by Huang Peiqiang, and the relevant content is introduced herein for illustration.
[0064] In some embodiments, the method for preparing a compound of formula E or a salt thereof, wherein the compound of formula D is a compound of formula D-1,
[0065] The method comprises the steps of reacting a compound of formula C with a compound of formula Z-1 in the presence of a condensing agent to form a compound of formula D-1,
[0066]
[0067] On the other hand, the method for preparing the compound of formula E or its salt further comprises the steps of converting the compound of formula C into the compound of formula D, and converting the compound of formula D into the compound of formula E.
[0068]
[0069] Among them, R 1 、R 2 are each independently selected from hydrogen, halogen or C 1-6 Alkyl, or R 1 and R 2 Together with adjacent carbon atoms, a 6-membered aryl or 5-6 heteroaryl group is formed, wherein the aryl or heteroaryl group is optionally substituted by halogen, C 1-6 Alkyl or C 1-6 Alkoxy substituted.
[0070] In some embodiments, the method for preparing a compound of formula E or a salt thereof, wherein the compound of formula D is a compound of formula D-1,
[0071] The method comprises the steps of reacting a compound of formula C with a compound of formula Z-1 in the presence of a condensing agent to form a compound of formula D-1, and reacting the compound of formula D-1 in the presence of hydrazine hydrate to form a compound of formula E.
[0072]
[0073] In other embodiments, the molar ratio of the compound of formula D-1 to hydrazine hydrate is 1:1 to 1:2, including but not limited to 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2 or any value between two numbers.
[0074] In other embodiments, the molar ratio of the compound of formula D-1 to hydrazine hydrate is 1:1.5.
[0075] Some embodiments provide a method for preparing a compound of formula E-1 or a salt thereof, comprising the steps of reacting a compound of formula C-1a in the presence of a condensing agent to form a compound of formula D-1a, and reacting the compound of formula D-1a in the presence of hydrazine hydrate to form a compound of formula E-1.
[0076]
[0077] Some embodiments provide a method for preparing a compound of formula E or a salt thereof, comprising reacting a compound of formula A under trimethylsulfonium halide / base conditions or trimethylsulfoxide halide / base conditions to form a compound of formula B, reacting the compound of formula B under acidic conditions to form a compound of formula C, then reacting the compound of formula C with a compound of formula Z in the presence of a condensing agent to form a compound of formula D, and reacting the compound of formula D in the presence of hydrazine hydrate to form a compound of formula E.
[0078]
[0079] In some embodiments, the method for preparing the compound of formula E or a salt thereof comprises the following steps:
[0080] Step 1) The compound of formula A is reacted under trimethylsulfonium iodide / potassium tert-butoxide or trimethylsulfonium iodide / potassium tert-butoxide to form a compound of formula B,
[0081] Step 2) the compound of formula B is reacted under trifluoroacetic acid / triethylsilane conditions to form a compound of formula C,
[0082] Step 3) The compound of formula C is reacted with the compound of formula Z in the presence of diisopropyl azodicarboxylate / triphenylphosphine to form a compound of formula D,
[0083] Step 4) The compound of formula D is reacted in the presence of hydrazine hydrate to form the compound of formula E.
[0084] Some embodiments provide a method for preparing a compound of formula E or a salt thereof, comprising reacting a compound of formula A-1 under trimethylsulfonium halide / base conditions or trimethylsulfoxide halide / base conditions to form a compound of formula B-1, reacting the compound of formula B-1 under acidic conditions to form a compound of formula C, then reacting the compound of formula C with formula Z-1 in the presence of a condensing agent to form a compound of formula D-1, and reacting the compound of formula D-1 in the presence of hydrazine hydrate to form a compound of formula E.
[0085]
[0086] Some embodiments provide a method for preparing a compound of formula E or a salt thereof, comprising reacting a compound of formula A-1a under trimethylsulfonium halide / base conditions or trimethylsulfoxide halide / base conditions to form a compound of formula B-1a, reacting the compound of formula B-1a under acidic conditions to form a compound of formula C-1a, then reacting the compound of formula C-1a with a compound of formula Z-1 in the presence of a condensing agent to form a compound of formula D-1a, and reacting the compound of formula D-1a in the presence of hydrazine hydrate to form a compound of formula E-1.
[0087]
[0088] In some embodiments, the method for preparing the compound of formula E or a salt thereof comprises the following steps:
[0089] Step 1) The compound of formula A-1a is reacted under trimethylsulfonium iodide / potassium tert-butoxide conditions or trimethylsulfonium iodide / potassium tert-butoxide conditions to form the compound of formula B-1a,
[0090] Step 2) The compound of formula B-1a is reacted under trifluoroacetic acid / triethylsilane conditions to form the compound of formula C-1a,
[0091] Step 3) The compound of formula C-1a is reacted with the compound of formula Z-1 in the presence of diisopropyl azodicarboxylate / triphenylphosphine to form the compound of formula D-1a,
[0092] Step 4) The compound of formula D-1a is reacted in the presence of hydrazine hydrate to form a compound of formula E.
[0093] Furthermore, the method for preparing the compound of formula A disclosed herein comprises the steps of reacting 3-chloro-1,2-propanediol with Ar3C-X to form an intermediate of formula a2, followed by cyclization to form the compound of formula A.
[0094] Wherein Ar is a 6-membered aryl or 5-6-membered heteroaryl, said aryl or heteroaryl being optionally substituted by halogen, C 1-6 Alkyl or C 1-6 The group is substituted by an alkoxy group, such as phenyl or pyridyl; and X is a halogen group, such as Cl.
[0095] In some embodiments, the compound of formula A in the method is a compound of formula A-1
[0096] In some embodiments, the method for preparing the compound of formula A-1 comprises reacting 3-chloro-1,2-propanediol with Ph3CCl to form an intermediate of formula a2-1, followed by a cyclization step to form the compound of formula A-1.
[0097]
[0098] In some embodiments, the method for preparing the compound of formula A-1 comprises reacting (R)-3-chloro-1,2-propanediol with Ph3CCl to form an intermediate of formula a2-1a, followed by a step of cyclization to form the compound of formula A-1a.
[0099]
[0100] In some embodiments, the cyclization reaction conditions of the present disclosure are alkaline conditions, and the base used is selected from, but not limited to, sodium hydroxide, potassium hydroxide, sodium tert-butoxide, or potassium tert-butoxide.
[0101] In other embodiments, the solvent used in the cyclization reaction of the present disclosure is selected from ethanol.
[0102] Some embodiments provide a method for preparing a compound of formula E or a salt thereof, comprising reacting a compound of formula a1 under Ar3C-X conditions to form a compound of formula a2, cyclizing the compound of formula a2 under alkaline conditions to form a compound of formula A, reacting the compound of formula A under trimethylsulfonium halide / base conditions or trimethylsulfoxide halide / base conditions to form a compound of formula B, reacting the compound of formula B under acidic conditions to form a compound of formula C, then reacting the compound of formula C with a compound of formula Z in the presence of a condensing agent to form a compound of formula D, and reacting the compound of formula D in the presence of hydrazine hydrate to form a compound of formula E.
[0103]
[0104] In some embodiments, the method for preparing the compound of formula E or a salt thereof comprises the following steps:
[0105] Step 1) The compound of formula a1 is reacted under triphenylmethyl chloride / triethylamine conditions to form a compound of formula a2,
[0106] Step 2) the compound of formula a2 is cyclized under potassium hydroxide conditions to form a compound of formula A,
[0107] Step 3) The compound of formula A is reacted under trimethylsulfonium iodide / potassium tert-butoxide or trimethylsulfonium iodide / potassium tert-butoxide to form a compound of formula B,
[0108] Step 4) the compound of formula B is reacted under trifluoroacetic acid / triethylsilane conditions to form a compound of formula C,
[0109] Step 5) The compound of formula C is reacted with the compound of formula Z in the presence of diisopropyl azodicarboxylate / triphenylphosphine to form a compound of formula D,
[0110] Step 6) The compound of formula D is reacted in the presence of hydrazine hydrate to form the compound of formula E.
[0111] Some embodiments provide a method for preparing a compound of formula E or a salt thereof, comprising reacting a compound of formula a1-1 under triphenylmethyl chloride conditions to form a compound of formula a2-1, cyclizing the compound of formula a2-1 under alkaline conditions to form a compound of formula A-1, reacting the compound of formula A-1 under trimethylsulfonium halide / base conditions or trimethylsulfoxide halide / base conditions to form a compound of formula B-1, reacting the compound of formula B-1 under acidic conditions to form a compound of formula C, then reacting the compound of formula C with formula Z-1 in the presence of a condensing agent to form a compound of formula D-1, and reacting the compound of formula D-1 in the presence of hydrazine hydrate to form a compound of formula E.
[0112]
[0113] In some embodiments, the method for preparing the compound of formula E or a salt thereof comprises the following steps:
[0114] Step 1) The compound of formula a1-1 is reacted under triphenylmethyl chloride / triethylamine conditions to form a compound of formula a2-1,
[0115] Step 2) The compound of formula a2-1 is cyclized under potassium hydroxide to form the compound of formula A-1,
[0116] Step 3) The compound of formula A-1 is reacted under trimethylsulfonium iodide / potassium tert-butoxide or trimethylsulfonium iodide / potassium tert-butoxide to form a compound of formula B-1,
[0117] Step 4) The compound of formula B-1 is reacted under trifluoroacetic acid / triethylsilane conditions to form a compound of formula C,
[0118] Step 5) The compound of formula C is reacted with the compound of formula Z-1 in the presence of diisopropyl azodicarboxylate / triphenylphosphine to form the compound of formula D-1,
[0119] Step 6) The compound of formula D-1 is reacted in the presence of hydrazine hydrate to form a compound of formula E.
[0120] Some embodiments provide a method for preparing a compound of formula E or a salt thereof, comprising reacting a compound of formula a1-1a under triphenylmethyl chloride conditions to form a compound of formula a2-1a, cyclizing the compound of formula a2-1a under alkaline conditions to form a compound of formula A-1a, reacting the compound of formula A-1a under trimethylsulfonium halide / base conditions or trimethylsulfoxide halide / base conditions to form a compound of formula B-1a, reacting the compound of formula B-1a under acidic conditions to form a compound of formula C-1a, then reacting the compound of formula C-1a with a compound of formula Z-1 in the presence of a condensing agent to form a compound of formula D-1a, and reacting the compound of formula D-1a in the presence of hydrazine hydrate to form a compound of formula E-1.
[0121]
[0122] In some embodiments, the method for preparing the compound of formula E or a salt thereof comprises the following steps:
[0123] Step 1) The compound of formula a1-1a is reacted under triphenylmethyl chloride / triethylamine conditions to form a compound of formula a2-1a,
[0124] Step 2) The compound of formula a2-1a is cyclized under potassium hydroxide to form the compound of formula A-1a,
[0125] Step 3) The compound of formula A-1a is reacted under trimethylsulfonium iodide / potassium tert-butoxide conditions or trimethylsulfonium iodide / potassium tert-butoxide conditions to form a compound of formula B-1a,
[0126] Step 4) The compound of formula B-1a is reacted under trifluoroacetic acid / triethylsilane conditions to form a compound of formula C-1a,
[0127] Step 5) The compound of formula C-1a reacts with the compound of formula Z-1 in the presence of diisopropyl azodicarboxylate / triphenylphosphine to form the compound of formula D-1a,
[0128] Step 6) The compound of formula D-1a is reacted in the presence of hydrazine hydrate to form the compound of formula E.
[0129] The present disclosure also provides a compound of formula B or a salt thereof,
[0130] Wherein Ar is a 6-membered aryl or 5-6-membered heteroaryl, said aryl or heteroaryl being optionally substituted by halogen, C 1-6 Alkyl or C 1-6 The moiety may be substituted with an alkoxy group, for example, phenyl or pyridyl.
[0131] In some embodiments, the compound of formula B is a compound of formula B-1
[0132] In some embodiments, the compound of formula B is a compound of formula B-1a or a compound of formula B-1b
[0133] In another aspect, the present disclosure also provides a compound of formula D or a salt thereof,
[0134] where R 1 、R 2 are each independently selected from hydrogen, halogen or C 1-6 Alkyl, or R 1 and R 2 Together with adjacent carbon atoms, a 6-membered aryl or 5-6 heteroaryl group is formed, wherein the aryl or heteroaryl group is optionally substituted by halogen, C 1-6 Alkyl or C 1-6 Alkoxy substituted.
[0135] In some embodiments, the compound of formula D is a compound of formula D-1
[0136] In some embodiments, the compound of formula D is a compound of formula D-1a or a compound of formula D-1a
[0137] In another aspect, the present disclosure also provides a method for preparing a compound of formula H or a salt thereof,
[0138] The method comprises the aforementioned method for preparing the compound of formula E, and the step of reacting the compound of formula F with the compound of formula E to form the compound of formula G.
[0139] where R 3 Selected from C 1-6 Alkyl group, preferably methyl or ethyl.
[0140] In some embodiments, the compound of formula H is
[0141] The method comprises the steps of reacting a compound of formula F-1 with a compound of formula E to form a compound of formula G-1
[0142]
[0143] In some embodiments, the compound of formula H is
[0144] The method comprises the steps of reacting a compound of formula F-1 with a compound of formula E-1a to form a compound of formula G-1
[0145]
[0146] Furthermore, the method for preparing the compound of formula H or its salt further comprises the step of reacting the compound of formula G in the presence of a reducing agent to form the compound of formula H, wherein the reducing agent is preferably iron powder.
[0147] Some embodiments provide a method for preparing a compound of formula H or a salt thereof, comprising the steps of reacting a compound of formula F with a compound of formula E to form a compound of formula G, and reacting the compound of formula G in the presence of a reducing agent to form a compound of formula H.
[0148]
[0149] Some embodiments provide a method for preparing a compound of formula H-1 or a salt thereof, comprising reacting a compound of formula F-1 with a compound of formula E to form a compound of formula G, and reacting the compound of formula G in the presence of a reducing agent to form a compound of formula H.
[0150]
[0151] Some embodiments provide a method for preparing a compound of formula H-1a or a salt thereof, comprising the steps of reacting a compound of formula F-1 with a compound of formula E-1a to form a compound of formula G-1a, and reacting the compound of formula G-1a in the presence of a reducing agent to form a compound of formula H-1a.
[0152]
[0153] In another aspect, the present disclosure also provides a method for preparing a compound of formula I or a salt thereof,
[0154] The method comprises the steps of reacting a compound of formula H with 2-halogeno-1,1,1-trimethoxyethane to form a compound of formula I,
[0155] where R 3 Selected from C 1-6 Alkyl, preferably methyl or ethyl; X is halogen, such as Cl.
[0156] In some embodiments, the compound of formula I is a compound of formula I-1,
[0157] The method comprises the steps of reacting a compound of formula H-1 with 2-chloro-1,1,1-trimethoxyethane to form a compound of formula I-1,
[0158]
[0159] In some embodiments, the compound of formula I is a compound of formula I-1,
[0160] The method comprises the steps of reacting a compound of formula H-1a with 2-chloro-1,1,1-trimethoxyethane to form a compound of formula I-1a,
[0161] The reaction operation can refer to the operation in WO2018 / 109607, and the relevant content is introduced into this article for illustration.
[0162] The present disclosure also provides the use of the aforementioned method for preparing the compound of formula E, the method for preparing the compound of formula H, the aforementioned compound of formula B, and the aforementioned compound of formula D in preparing a GLP-1 receptor agonist.
[0163] In some embodiments, the GLP-1 receptor agonist is selected from, but not limited to:
[0164]
[0165] The present disclosure also provides a method for preparing a compound of formula AA or a salt thereof, the method comprising the steps of the aforementioned method for preparing a compound of formula E or the aforementioned method for preparing a compound of formula H,
[0166]
[0167] Furthermore, the method for preparing the compound of formula AA or a salt thereof further comprises the step of reacting the compound of formula AA-1 with the compound of formula H-1a to form the compound of formula AA-2.
[0168]
[0169] The reaction conditions and operations are described in WO2018 / 109607, and the relevant contents are introduced herein for illustration.
[0170] The present disclosure also provides a method for preparing a compound of formula AA or a salt thereof, the method comprising the steps of the aforementioned method for preparing a compound of formula E or the aforementioned method for preparing a compound of formula H,
[0171]
[0172] Furthermore, the method for preparing the compound of formula BB or its salt further comprises the step of reacting the compound of formula BB-1 with the compound of formula H-1a to form the compound of formula BB-2.
[0173]
[0174] The reaction conditions and operations refer to those in WO2022007979, and the relevant contents are introduced herein for illustration.
[0175] The preparation method disclosed herein further comprises one or more steps of filtration, washing, drying, concentration or recrystallization.
[0176] Salts of the disclosed compounds / intermediates include, but are not limited to, addition salts of the free form of the compounds / intermediates with acids or bases, wherein the acid used to form the salts includes, but is not limited to, hydrochloric acid or methanesulfonic acid. In some embodiments, salts of the compounds / intermediates include, but are not limited to, hydrochloride, p-toluenesulfonate, methanesulfonate, or oxalate.
[0177] The terms "to form" and "to convert" do not necessarily imply a single-step conversion reaction between two substrates; they may be a single-step or multi-step reaction. If an intermediate contains a protecting group, the intermediate is subjected to a one-step removal of the protecting group and then reacted with the corresponding substrate to obtain the corresponding target product.
[0178] The numerical values in this disclosure are instrumental measurements and are subject to a certain degree of error. Generally speaking, within a reasonable error range of plus or minus 10%. The context in which the numerical value is used must be considered. For example, the particle size of an active ingredient, where the error after measurement does not exceed plus or minus 10%, may be plus or minus 9%, plus or minus 8%, plus or minus 7%, plus or minus 6%, plus or minus 5%, plus or minus 4%, plus or minus 3%, plus or minus 2%, or plus or minus 1%, preferably plus or minus 5%.
[0179] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if chiral isomers exist in the chemical structure, the bond Can be or or include both and Two configurations. Indicates the presence of chiral isomers in the structure, and also contains or Two configurations.
[0180] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, including alkyl groups having 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl.
[0181] The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy.
[0182] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0183] "Aryl" refers to a 6-membered all-carbon monocyclic or fused polycyclic (ie, rings that share adjacent pairs of carbon atoms) group having a conjugated π electron system, such as phenyl. Aryl groups can be substituted or unsubstituted.
[0184] "Heteroaryl" refers to a heteroaromatic system containing 5 to 6 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. Heteroaryl groups can be substituted or unsubstituted.
[0185] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in a group are independently replaced by a corresponding number of substituents. DETAILED DESCRIPTION
[0186] The present disclosure is further described below with reference to examples, but these examples are not intended to limit the scope of the present disclosure.
[0187] Experimental methods in the examples of this disclosure that do not specify specific conditions are generally based on conventional conditions or the conditions recommended by the raw material or product manufacturers. Reagents without specific sources are conventional reagents purchased from the market.
[0188] The structures of the compounds were confirmed by nuclear magnetic resonance (NMR) and / or mass spectroscopy (MS). NMR shifts (δ) are given in units of 10-6 (ppm).
[0189] NMR measurements were performed using a Bruker AVANCE-400 nuclear magnetic spectrometer, and the solvent was deuterated chloroform (CDCl3).
[0190] MS was determined using a Waters Micromass Quattro micro API triple quadrupole mass spectrometer in positive / negative ion mode with a mass scan range of 120-1300.
[0191] The thin layer chromatography silica gel plate used was Yantai Huanghai HSGF254 silica gel plate. The specification of the silica gel plate used in thin layer chromatography (TLC) was 0.2 mm ± 0.03 mm. The specification used for thin layer chromatography separation and purification products was 0.4 mm - 0.5 mm.
[0192] Embodiment 1:
[0193]
[0194] Step 1: Synthesis of compound 1b
[0195] To a 500 mL reaction flask, add (R)-3-chloro-1,2-propanediol, compound 1a (10.0 g, 90.5 mmol), DCM (100 mL), and triethylamine (10.80 g, 106.8 mmol). The reaction system was cooled to approximately 0°C, and Ph3CC1 (25.72 g, 92.3 mmol) was added portionwise. The temperature was naturally raised to 25°C, and the reaction was stirred. TLC indicated complete reaction. The reaction solution was concentrated to dryness under reduced pressure to obtain (R)-1-chloro-3-(trityloxy)propan-2-ol, compound 1b, as a colorless oil. The product was directly carried to the next step without further purification.
[0196] Step 2: Synthesis of compound 1c
[0197] In a 500 mL reaction flask, raw material 1b (31.92 g, 90.5 mmol) and EtOH (100 mL) were added, and the temperature was lowered to about 0°C. KOH (5.08 g, 90.5 mmol) was added portionwise. After addition, the temperature was naturally raised to 25°C. The mixture was stirred for reaction. TLC showed that the raw material had reacted completely. The reaction solution was concentrated to dryness under reduced pressure to obtain (S)-2-((trityloxy)methyl)oxirane as a white solid, compound 1c (22.90 g, two-step yield: 79.9%).
[0198] 1 H-NMR (400M Hz, CDCl3) δ7.47-7.44(m,6H),7.31-7.21(m,9H),3.33-3.30(m,1H),3.16-3.09(m,2H),2.77-2.75(m,1H),2.62-2.60(m,1H).
[0199] Step 3: Synthesis of compound 1e
[0200] In a 250 mL three-necked reaction flask, compound 1c (5.0 g, 15.80 mmol) and tert-butanol (30 mL) were added, followed by trimethylsulfoxide iodide, compound 1d (3.83 g, 17.38 mmol), and potassium tert-butoxide (1.95 g, 17.38 mmol). The mixture was heated to 60°C and stirred. TLC indicated complete reaction. The reaction mixture was quenched by pouring into ice-cold saturated ammonium chloride solution (30 mL) and extracted three times with ethyl acetate (30 mL x 3). The combined extracts were dried over anhydrous sodium sulfate, filtered, and the filtrate evaporated to dryness under reduced pressure to afford (S)-2-((trityloxy)methyl)oxetane as a white solid, compound 1e (3.2 g, yield: 62.0%).
[0201] 1 H-NMR (400M Hz, CDCl3) δ7.52-7.49(m,6H),7.31-7.21(m,9H),4.98-4.92(m,1H),4.68(t,J=7.2Hz,2H),3.29-3.19(m,2H),2.70-2.55(m,2H).
[0202] Step 4: Synthesis of Compound 1f
[0203] To a 100 mL reaction flask, 1e (1.1 g, 3.329 mmol) and DCM (11 mL) were added, along with Et3SiH (0.47 g, 3.995 mmol). The reaction mixture was cooled to approximately -10°C and a solution of trifluoroacetic acid (1.14 g, 9.987 mmol) in DCM (1 mL) was slowly added dropwise over 10-30 min. The mixture was stirred for 30 min. A spot plate was taken, and TLC indicated complete reaction. Pyridine (1.05 g, 13.32 mmol, 4.0 eq) was slowly added dropwise to quench the reaction. The mixture was then concentrated under reduced pressure to afford (S)-oxetane-2-methanol, compound 1f. The reaction mixture was directly carried out in the next step without further purification.
[0204] 1 H-NMR (400M Hz, CDCl3) δ4.97-4.91(m,1H),4.73-4.69(m,1H),4.56-4.51(m,1H),3.79-3.97(m,1H),3.65-3.61(m,1H),2.72-2.57(m,2H).
[0205] Step 5: Synthesis of compound 1h
[0206] In a 250 mL reaction flask, 1f (3.0 g, 34.05 mmol) and THF (45 mL) were added, followed by phthalimide, compound 1g (5.01 g, 34.05 mmol), and PPh3 (9.82 g, 37.46 mmol). The mixture was cooled to 0°C, and DIAD (7.57 g, 37.46 mmol) was added dropwise over 10-30 min. The temperature was raised to 25°C and stirred overnight. When TLC showed completion of the reaction, ice water (30 mL) was added to quench the reaction solution. The THF was concentrated under reduced pressure, and the mixture was extracted three times with methyl tert-butyl ether (30 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give (S)-2-(oxetan-2-ylmethyl)isoindoline-1,3-dione, compound 1h. The product was directly reacted in the next step as a light yellow solid with a total yield of approximately 80%.
[0207] MS (ESI): m / z 218.10 [M+1] +
[0208] 1H-NMR(400M Hz, CDCl3)δ7.87-7.84(m,2H),7.73-7.71(m,2H),5.09-5.02(m,1H),4.68-4.56(m ,2H),4.10-4.05(m,1H),3.94-3.89(m,1H),2.77-2.68(m,1H),2.58-2.49(m,1H).
[0209] Step 6: Synthesis of Compound 1
[0210] In a 100 mL reaction bottle, add raw material 1h (2.0 g, 9.21 mmol) and MeOH (20 mL), then add NH2NH2.H2O (0.86 g, 13.82 mmol, 80%), and stir at 65 ° C. TLC shows the reaction is complete. The solvent was partially evaporated under reduced pressure, DCM (20 mL) was added, and the solvent was partially evaporated under reduced pressure, and DCM (20 mL) was added again. The product was filtered, the filter cake was washed with DCM (10 mL), the filter cake was discarded, the filtrate was collected, the filtrate was washed with saturated sodium chloride solution (10 mL), the aqueous phase was extracted with DCM (10 mL * 3 times), the organic phases were combined, and the solvent was partially evaporated under reduced pressure to give a DCM solution containing the product (about 10 mL), TsOH.H2O (1.75 g) was added and stirred to form a salt, and EtOAc (10 mL) was added, concentrated under reduced pressure, cooled and crystallized, filtered, the filter cake was washed with EtOAc (about 10 mL), dried, and dried under reduced pressure to give 1.9 g of a white solid product with a yield of 79.5%.
[0211] MS (ESI): m / z 88.10 [M+1] +
[0212] 1 H-NMR(400M Hz,DMSO-d6)δ7.91(brs,3H),7.49(d,J=8.0Hz,2H),7.12(d,J=8.0Hz,2H),4.91-4.84(m,1H),4.58-4.52(m,1H ),4.49-4.44(m,1H),3.15-3.09(m,1H),3.05-3.00(m,1H),2.71-2.62(m,1H),2.49-2.44(m,1H),2.29(s,3H).
Claims
1. Method for preparing a compound of formula E or a salt thereof The method comprises the steps of reacting a compound of formula A under trimethylsulfonium halide / base conditions or trimethylsulfoxide halide / base conditions to form a compound of formula B, in, Ar is a 6-membered aryl or 5-6-membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted by halogen, C 1-6 Alkyl or C 1-6 The moiety may be substituted with an alkoxy group, for example, phenyl or pyridyl.
2. The method according to claim 1, wherein the trimethylsulfonium halide is trimethylsulfonium iodide, and the trimethylsulfoxide halide is trimethylsulfoxide iodide.
3. The method according to claim 1 or 2, wherein the base is selected from potassium tert-butoxide, sodium tert-butoxide, lithium tert-butoxide, potassium tert-amylate, sodium tert-amylate, lithium tert-amylate, potassium hydride, sodium hydride, n-butyllithium, bis(trimethylsilyl)lithium amide, bis(trimethylsilyl)sodium amide or bis(trimethylsilyl)potassium amide, preferably potassium tert-butoxide.
4. The method according to any one of claims 1 to 3, wherein the solvent used for the reaction of the compound of formula A is selected from tert-butyl alcohol, dimethyl sulfoxide, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone or tert-amyl alcohol, preferably tert-butyl alcohol.
5. The method according to any one of claims 1 to 4, further comprising the step of reacting the compound of formula B under acid conditions to form the compound of formula C in, Ar is defined in claim 1, and the acid is preferably at least one of trifluoroacetic acid, trimethylsilane or triethylsilane, more preferably trifluoroacetic acid / triethylsilane.
6. The method according to any one of claims 1 to 5, comprising the steps of converting the compound of formula C into the compound of formula D, and converting the compound of formula D into the compound of formula E in, R 1 , R 2 are each independently selected from hydrogen, halogen or C 1-6 Alkyl, or R 1 and R 2 Together with adjacent carbon atoms, a 6-membered aryl or 5-6-membered heteroaryl group is formed, wherein the aryl or heteroaryl group is optionally substituted by halogen, C 1-6 Alkyl or C 1-6 Preferably, the method further comprises the steps of reacting the compound of formula C in the presence of a condensing agent to form a compound of formula D-1, and reacting the compound of formula D-1 in the presence of hydrazine hydrate to form oxetane-2-ylmethylamine. The compound of formula D is a compound of formula D-1; more preferably, the compound of formula E is 7. The method according to any one of claims 1 to 6, comprising the steps of reacting the compound of formula A-1 under trimethylsulfonium halide / base conditions to form the compound of formula B-1, reacting the compound of formula B-1 under acid conditions to form the compound of formula C, then reacting the compound of formula C in the presence of a condensing agent to form the compound of formula D-1, and reacting the compound of formula D-1 in the presence of hydrazine hydrate to form the compound of formula E, Preferably, the compound of formula E is 8. A compound of formula B or a salt thereof, Wherein Ar is a 6-membered aryl or 5-6-membered heteroaryl, the aryl or heteroaryl is optionally substituted by halogen, C 1-6 Alkyl or C 1-6 Alkoxy substituted, for example phenyl or pyridyl; Further, the compound of formula B is preferably a compound of formula B-1 9. A method for preparing a compound of formula H or a salt thereof, The method comprises the method according to any one of claims 1 to 7, and the step of reacting a compound of formula F with a compound of formula E to form a compound of formula G, Where R 3 Selected from C 1-6 The alkyl group is preferably a methyl group or an ethyl group.
10. The method according to claim 9, further comprising the step of reacting the compound of formula G in the presence of a reducing agent to form a compound of formula H, wherein the reducing agent is preferably iron powder.
11. Use of the method according to any one of claims 1 to 7, the method according to claim 9 or 10, or the compound of formula B according to claim 8 in the preparation of a GLP-1 receptor agonist.
12. A method for preparing a compound of formula AA or a salt thereof, the method comprising the method according to any one of claims 1 to 7 or the method according to claim 9 or 10, 13. A method for preparing a compound of formula BB or a salt thereof, the method comprising the method according to any one of claims 1 to 7 or the method according to claim 9 or 10,
